Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sollpura's Future After No Vote From Panel Might Include More Trials, Adult Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Gastrointestinal Drugs Advisory Committee says in lopsided votes that Lilly's exocrine pancreatic insufficiency drug candidate Sollpura (liprotamase) lacks proof of efficacy.
Advertisement

Related Content

Aptalis’ Ultresa And Viokace Join Crowded Marketplace Of Pancreatic Enzyme Products
Can You Still Use Surrogate Markers In A Crowded Drug Class? Sollpura Panel Recommends BMI, Weight Endpoints
Can You Still Use Surrogate Markers In A Crowded Drug Class? Sollpura Panel Recommends BMI, Weight Endpoints
Lilly's Solpura Advisory Committee Could Hinge On Manufacturing Issues
This Little Pig-Free Product Goes To Market? Alnara's High Hopes For A PERT
This Little Pig-Free Product Goes To Market? Alnara's High Hopes For A PERT

Topics

Advertisement
UsernamePublicRestriction

Register

PS071687

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel